Evaluating the safety of autologous intra papillary muscle injection of bone marrow stem cell in patients with up to moderate ischemic mitral regurgitation: A Phase II clinical trial

Rajaie cardiovascular medical and research center0 个研究点目标入组 30 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•1.Recent posterior-inferior MI* (= 2 weeks but = 2 months)
•2. Planned complete Revascularization,
•3. No evidence of myocardial viability in the infarct area of PM, as shown by a preoperative low-dose dobutamine echocardiography. (Akinetic or dyskinetic segments seen on echocardiography, and lack of myocardial viability on dobutamine echocardiography)
•4.Up to moderate Ischemic Mitral Regurgitation
•5.LVEF =25 %
•Exclusion criteria:
•1.Previous myocardial revascularization;
•2.Not complete revascularization during CABG
•3.Left ventricular aneurysm;
•4.Permanent or persistent ventricular arrhythmias;
•5.Severe valvular disease;
•6.History of any hematological disease, including leucopenia (=3.000 white cells/µL), thrombocytopenia (= 120.000 platelets/µL), or thrombocytosis (= 450.000 platelets/µL);
•7. Hepatic or renal dysfunction (serum creatinine = 2 mg/mL, ALT = 2 times of normal value);
•8.Positive history of HIV
•9. Evidence of malignant diseases or unwillingness to participate.

发起方

Rajaie cardiovascular medical and research center